---
title: Fujifilm Pharmaceuticals U.S.A., Inc vs Sophia CDMO
slug_a: fujifilmpharma
slug_b: sophiacdmo
site: cdmo
review_signal_gate: closed
canonical_path: /compare/fujifilmpharma/sophiacdmo
generated_by: BioBM Editorial AI
---

# Fujifilm Pharmaceuticals U.S.A., Inc vs Sophia CDMO

This comparison is auto-generated by BioBM Editorial AI and intended as an evidence-oriented side-by-side reference.

## Company A

Fujifilm Pharmaceuticals U.S.A., Inc (fujifilmpharma) is listed for cdmo. CDMO specializing in liposome and lipid nanoparticle (LNP) formulation development and GMP manufacturing from bench to commercial scale, with mRNA process development and aseptic fill-finish capabilities.

Services: 9. Modalities: 2. Indications: 2. Locations: 0. Certifications: 0. Directory-wide review aggregates for this site are withheld until the review signal gate opens. The strongest documented coverage currently appears in services (9).

Review summary: Review summary withheld until site-level review gate opens.

## Company B

Sophia CDMO (sophiacdmo) is listed for cdmo. European CDMO specializing in microbial and precision fermentation up to 40,000 L across two integrated sites (Pamplona, Spain and Basel, Switzerland), with core strengths in E. coli expression, animal health biologics, probiotics, and complex CMC programs requiring scale-up discipline and impurity control.

Services: 18. Modalities: 5. Indications: 0. Locations: 2. Certifications: 0. Directory-wide review aggregates for this site are withheld until the review signal gate opens. The strongest documented coverage currently appears in services (18).

Review summary: Review summary withheld until site-level review gate opens.